SCHEMBL3523631

SCHEMBL3523631

O=C(O)c1c(O)c(-c2ccccn2)cc2nccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.47
KDM4E B2RXH2 4/20 0.43
KDM6B O15054 1/20 0.43
KDM4A O75164 1/20 0.43
KDM5C P41229 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
KDM3A Q9Y4C1 1/20 0.43
PIN1 Q13526 1/20 0.40
DHODH Q02127 3/20 0.39
BRD4 O60885 1/20 0.37
BRD2 P25440 1/20 0.37
BRD3 Q15059 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
LMNA P02545 1/20 0.37
NAPRT Q6XQN6 1/20 0.37
P4HTM Q9NXG6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766921 0.84 EGLN3 (0.69) EGLN3KDM6BKDM4CKDM2AKDM3A
SCHEMBL3525060 0.82 DHODH (0.45) EGLN3KDM4EKDM6BKDM4AKDM5C
SCHEMBL3525718 0.80 EGLN3 (0.44) EGLN3KDM4EKDM4CDHODHLMNA
SCHEMBL3524401 0.73 EGLN3 (0.46) EGLN3DHODHLMNAPDE10A
SCHEMBL3524985 0.72 EGLN3 (0.40) EGLN3KDM4EKDM4ABRD4L3MBTL1
SCHEMBL25529048 0.71 KDM4E (0.46) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL3519604 0.71 KDM4E (0.45) EGLN3KDM4EDHODHALDH1A1PDE10A
SCHEMBL3520296 0.71 EGLN3 (0.37) EGLN3KDM4EDHODHTHRBLMNA
SCHEMBL3521085 0.71 DPP4 (0.44) EGLN3KDM4EKDM4CDHODHLMNA
SCHEMBL3522213 0.70 EGLN3 (0.83) EGLN3KDM6BKDM4CKDM2AKDM3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885KDM4E 176/4885KDM6B 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.